Medicines and Healthcare products Regulatory Agency

CERTIFICATE NUMBER : UK API 1108 Insp GMP/GDP 1108/1893-0019

Certificate of GMP Compliance Of A Manufacturer(1),(2)

Part 1
Issued following an inspection in accordance with :

Regulation 331A of The Human Medicines Regulations 2012 (SI 2012/1916)

  The competent authority of United Kingdom confirms the following :
The Manufacturer : MACFARLAN SMITH LIMITED
 
Site address : MACFARLAN SMITH LIMITED, 10 WHEATFIELD ROAD, EDINBURGH, EH11 2QA, UNITED KINGDOM
 

Is an active substance manufacturer that has been inspected in accordance with Regulation 327 of The Human Medicines Regulations 2012 (SI 2012/1916).

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 19/12/2024, it is considered that it complies with

  • The principles of GMP for active substances referred to in Regulation B17 and C17 of the Human Medicines Regulations 2012 (SI 2012/1916)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in MHRA-GMDP. If it does not appear, please contact the issuing authority.


  • (1) Guidance on the interpretation of this template can be found in the Help menu of MHRA-GMDP database.
  • (2) These requirements fulfil the GMP recommendations of WHO.
Part 2
Human Medicinal Products

Manufacture of active substance. Names of substances subject to inspection:

  • [2000007584] FENTANYL CITRATE
  • [2000015376] CODEINE SULFATE
  • [2000006818] SUFENTANIL CITRATE
  • [2000007868] HYDROMORPHONE HYDROCHLORIDE
  • [1000007438] OXYCODONE
  • [2000008247] MORPHINE HYDROCHLORIDE
  • [2000008051] APOMORPHINE HYDROCHLORIDE
  • [2000008305] METHYLPHENIDATE HYDROCHLORIDE
  • [1000003943] COCAINE
  • [2000007776] DIAMORPHINE HYDROCHLORIDE
  • [2000007435] REMIFENTANIL HYDROCHLORIDE
  • [2000008238] NALOXONE HYDROCHLORIDE
  • [2000008277] BUPRENORPHINE HYDROCHLORIDE
  • [4000006163] MORPHINE SULFATE
  • [1000003221] DIAMORPHINE
  • [2000008540] ALFENTANIL HYDROCHLORIDE
  • [1000002290] FENTANYL
  • [4000008052] DIHYDROCODEINE HYDROGEN TARTRATE
  • [2000007943] COCAINE HYDROCHLORIDE
  • [1000003912] CODEINE
  • [1000010779] MORPHINE
  • [2000008245] MORPHINE TARTRATE
  • [4000006570] CODEINE PHOSPHATE HEMIHYDRATE
  • [1000007171] BUPRENORPHINE
  • [2000006722] OXYCODONE HYDROCHLORIDE
  • [1000009886] PHOLCODINE
Active Substances
3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES
FENTANYL CITRATE
3.1Manufacture of Active Substance by Chemical Synthesis
3.1.1  Manufacture Of Active Substance Intermediates

3.1.2  Manufacture Of Crude Active Substance

3.1.3  Salt Formation/Purification steps (eg. Crystallisation)
Salt formation
3.5General Finishing Steps
3.5.1  Physical Processing Steps
Drying, Milling
3.5.2  Primary Packaging

3.5.3  Secondary Packaging

3.6Quality Control Testing
3.6.1  Physical / Chemical testing

3.6.2  Microbiological testing (excluding sterility testing)

CODEINE SULFATE
3.1Manufacture of Active Substance by Chemical Synthesis
3.1.1  Manufacture Of Active Substance Intermediates

3.1.2  Manufacture Of Crude Active Substance

3.1.3  Salt Formation/Purification steps (eg. Crystallisation)
Salt formation, Crystallisation
3.5General Finishing Steps
3.5.1  Physical Processing Steps
Drying, Milling
3.5.2  Primary Packaging

3.5.3  Secondary Packaging

3.6Quality Control Testing
3.6.1  Physical / Chemical testing

SUFENTANIL CITRATE
3.1Manufacture of Active Substance by Chemical Synthesis
3.1.1  Manufacture Of Active Substance Intermediates

3.1.2  Manufacture Of Crude Active Substance

3.1.3  Salt Formation/Purification steps (eg. Crystallisation)
Salt formation, Recrystallisation
3.5General Finishing Steps
3.5.1  Physical Processing Steps
Drying, Sieving
3.5.2  Primary Packaging

3.5.3  Secondary Packaging

3.6Quality Control Testing
3.6.1  Physical / Chemical testing

3.6.2  Microbiological testing (excluding sterility testing)

HYDROMORPHONE HYDROCHLORIDE
3.1Manufacture of Active Substance by Chemical Synthesis
3.1.1  Manufacture Of Active Substance Intermediates

3.1.2  Manufacture Of Crude Active Substance

3.1.3  Salt Formation/Purification steps (eg. Crystallisation)
Salt formation, Recrystallisation
3.5General Finishing Steps
3.5.1  Physical Processing Steps
Drying, Milling
3.5.2  Primary Packaging

3.5.3  Secondary Packaging

3.6Quality Control Testing
3.6.1  Physical / Chemical testing

3.6.2  Microbiological testing (excluding sterility testing)

OXYCODONE
3.1Manufacture of Active Substance by Chemical Synthesis
3.1.1  Manufacture Of Active Substance Intermediates

3.1.2  Manufacture Of Crude Active Substance

3.1.3  Salt Formation/Purification steps (eg. Crystallisation)
Crytsallisation
3.5General Finishing Steps
3.5.1  Physical Processing Steps
Drying and milling
3.5.2  Primary Packaging

3.5.3  Secondary Packaging

3.6Quality Control Testing
3.6.1  Physical / Chemical testing

MORPHINE HYDROCHLORIDE
3.1Manufacture of Active Substance by Chemical Synthesis
3.1.1  Manufacture Of Active Substance Intermediates

3.1.2  Manufacture Of Crude Active Substance

3.1.3  Salt Formation/Purification steps (eg. Crystallisation)
Crystallisation
3.5General Finishing Steps
3.5.1  Physical Processing Steps
Drying, Milling
3.5.2  Primary Packaging

3.5.3  Secondary Packaging

3.6Quality Control Testing
3.6.1  Physical / Chemical testing

3.6.2  Microbiological testing (excluding sterility testing)

APOMORPHINE HYDROCHLORIDE
3.1Manufacture of Active Substance by Chemical Synthesis
3.1.1  Manufacture Of Active Substance Intermediates

3.1.2  Manufacture Of Crude Active Substance

3.1.3  Salt Formation/Purification steps (eg. Crystallisation)
Salt Formation, Filtration, Recrystallisation
3.5General Finishing Steps
3.5.1  Physical Processing Steps
Drying, Milling
3.5.2  Primary Packaging

3.5.3  Secondary Packaging

3.6Quality Control Testing
3.6.1  Physical / Chemical testing

3.6.2  Microbiological testing (excluding sterility testing)

METHYLPHENIDATE HYDROCHLORIDE
3.1Manufacture of Active Substance by Chemical Synthesis
3.1.1  Manufacture Of Active Substance Intermediates

3.1.2  Manufacture Of Crude Active Substance

3.1.3  Salt Formation/Purification steps (eg. Crystallisation)
Salt formation, Crystallisation
3.5General Finishing Steps
3.5.1  Physical Processing Steps
Drying, Milling
3.5.2  Primary Packaging

3.5.3  Secondary Packaging

3.6Quality Control Testing
3.6.1  Physical / Chemical testing

COCAINE
3.1Manufacture of Active Substance by Chemical Synthesis
3.1.1  Manufacture Of Active Substance Intermediates

3.1.2  Manufacture Of Crude Active Substance

3.1.3  Salt Formation/Purification steps (eg. Crystallisation)
Recrystallisation
3.5General Finishing Steps
3.5.1  Physical Processing Steps
Drying, Milling
3.5.2  Primary Packaging

3.5.3  Secondary Packaging

3.6Quality Control Testing
3.6.1  Physical / Chemical testing

DIAMORPHINE HYDROCHLORIDE
3.1Manufacture of Active Substance by Chemical Synthesis
3.1.1  Manufacture Of Active Substance Intermediates

3.1.2  Manufacture Of Crude Active Substance

3.1.3  Salt Formation/Purification steps (eg. Crystallisation)
Salt Formation
3.5General Finishing Steps
3.5.1  Physical Processing Steps
Drying, Milling
3.5.2  Primary Packaging

3.5.3  Secondary Packaging

3.6Quality Control Testing
3.6.1  Physical / Chemical testing

3.6.2  Microbiological testing (excluding sterility testing)

REMIFENTANIL HYDROCHLORIDE
3.1Manufacture of Active Substance by Chemical Synthesis
3.1.1  Manufacture Of Active Substance Intermediates

3.1.2  Manufacture Of Crude Active Substance

3.1.3  Salt Formation/Purification steps (eg. Crystallisation)
Salt Formation, Recrystallisation
3.5General Finishing Steps
3.5.1  Physical Processing Steps
Drying, Sieving
3.5.2  Primary Packaging

3.5.3  Secondary Packaging

3.6Quality Control Testing
3.6.1  Physical / Chemical testing

3.6.2  Microbiological testing (excluding sterility testing)

NALOXONE HYDROCHLORIDE
3.1Manufacture of Active Substance by Chemical Synthesis
3.1.1  Manufacture Of Active Substance Intermediates

3.1.2  Manufacture Of Crude Active Substance

3.1.3  Salt Formation/Purification steps (eg. Crystallisation)
Salt formation, Recrystallisation
3.5General Finishing Steps
3.5.1  Physical Processing Steps
Drying, Milling
3.5.2  Primary Packaging

3.5.3  Secondary Packaging

3.6Quality Control Testing
3.6.1  Physical / Chemical testing

3.6.2  Microbiological testing (excluding sterility testing)

BUPRENORPHINE HYDROCHLORIDE
3.1Manufacture of Active Substance by Chemical Synthesis
3.1.1  Manufacture Of Active Substance Intermediates

3.1.2  Manufacture Of Crude Active Substance

3.1.3  Salt Formation/Purification steps (eg. Crystallisation)
Salt Formation, Crystallisation
3.5General Finishing Steps
3.5.1  Physical Processing Steps
Drying, Milling
3.5.2  Primary Packaging

3.5.3  Secondary Packaging

3.6Quality Control Testing
3.6.1  Physical / Chemical testing

3.6.2  Microbiological testing (excluding sterility testing)

MORPHINE SULFATE
3.1Manufacture of Active Substance by Chemical Synthesis
3.1.1  Manufacture Of Active Substance Intermediates

3.1.2  Manufacture Of Crude Active Substance

3.1.3  Salt Formation/Purification steps (eg. Crystallisation)
Salt formation, Crystallisation
3.5General Finishing Steps
3.5.1  Physical Processing Steps
Drying, Milling
3.5.2  Primary Packaging

3.5.3  Secondary Packaging

3.6Quality Control Testing
3.6.1  Physical / Chemical testing

3.6.2  Microbiological testing (excluding sterility testing)

DIAMORPHINE
3.1Manufacture of Active Substance by Chemical Synthesis
3.1.1  Manufacture Of Active Substance Intermediates

3.1.2  Manufacture Of Crude Active Substance

3.1.3  Salt Formation/Purification steps (eg. Crystallisation)
Recrystallisation
3.5General Finishing Steps
3.5.1  Physical Processing Steps
Drying, Milling
3.5.2  Primary Packaging

3.5.3  Secondary Packaging

3.6Quality Control Testing
3.6.1  Physical / Chemical testing

ALFENTANIL HYDROCHLORIDE
3.1Manufacture of Active Substance by Chemical Synthesis
3.1.1  Manufacture Of Active Substance Intermediates

3.1.2  Manufacture Of Crude Active Substance

3.1.3  Salt Formation/Purification steps (eg. Crystallisation)
Salt Formation, Filtration, Recrystallisation
3.5General Finishing Steps
3.5.1  Physical Processing Steps
Drying, Sieving
3.5.2  Primary Packaging

3.5.3  Secondary Packaging

3.6Quality Control Testing
3.6.1  Physical / Chemical testing

3.6.2  Microbiological testing (excluding sterility testing)

FENTANYL
3.1Manufacture of Active Substance by Chemical Synthesis
3.1.1  Manufacture Of Active Substance Intermediates

3.1.2  Manufacture Of Crude Active Substance

3.1.3  Salt Formation/Purification steps (eg. Crystallisation)
Recrystallisation
3.5General Finishing Steps
3.5.1  Physical Processing Steps
Drying, Milling
3.5.2  Primary Packaging

3.5.3  Secondary Packaging

3.6Quality Control Testing
3.6.1  Physical / Chemical testing

DIHYDROCODEINE HYDROGEN TARTRATE
3.1Manufacture of Active Substance by Chemical Synthesis
3.1.1  Manufacture Of Active Substance Intermediates

3.1.2  Manufacture Of Crude Active Substance

3.1.3  Salt Formation/Purification steps (eg. Crystallisation)
Salt formation, Crystallisation
3.5General Finishing Steps
3.5.1  Physical Processing Steps
Drying, Milling
3.5.2  Primary Packaging

3.5.3  Secondary Packaging

3.6Quality Control Testing
3.6.1  Physical / Chemical testing

COCAINE HYDROCHLORIDE
3.1Manufacture of Active Substance by Chemical Synthesis
3.1.1  Manufacture Of Active Substance Intermediates

3.1.2  Manufacture Of Crude Active Substance

3.1.3  Salt Formation/Purification steps (eg. Crystallisation)
Salt formation, Crystallisation
3.5General Finishing Steps
3.5.1  Physical Processing Steps
Drying, Milling
3.5.2  Primary Packaging

3.5.3  Secondary Packaging

3.6Quality Control Testing
3.6.1  Physical / Chemical testing

CODEINE
3.1Manufacture of Active Substance by Chemical Synthesis
3.1.1  Manufacture Of Active Substance Intermediates

3.1.2  Manufacture Of Crude Active Substance

3.1.3  Salt Formation/Purification steps (eg. Crystallisation)
Crystallisation
3.5General Finishing Steps
3.5.1  Physical Processing Steps
Drying and milling
3.5.2  Primary Packaging

3.5.3  Secondary Packaging

3.6Quality Control Testing
3.6.1  Physical / Chemical testing

MORPHINE
3.1Manufacture of Active Substance by Chemical Synthesis
3.1.1  Manufacture Of Active Substance Intermediates

3.1.2  Manufacture Of Crude Active Substance

3.1.3  Salt Formation/Purification steps (eg. Crystallisation)
Crystallisation
3.5General Finishing Steps
3.5.1  Physical Processing Steps
Drying, Milling
3.5.2  Primary Packaging

3.5.3  Secondary Packaging

3.6Quality Control Testing
3.6.1  Physical / Chemical testing

MORPHINE TARTRATE
3.1Manufacture of Active Substance by Chemical Synthesis
3.1.1  Manufacture Of Active Substance Intermediates

3.1.2  Manufacture Of Crude Active Substance

3.1.3  Salt Formation/Purification steps (eg. Crystallisation)
Salt formation
3.5General Finishing Steps
3.5.1  Physical Processing Steps
Drying, Milling
3.5.2  Primary Packaging

3.5.3  Secondary Packaging

3.6Quality Control Testing
3.6.1  Physical / Chemical testing

CODEINE PHOSPHATE HEMIHYDRATE
3.1Manufacture of Active Substance by Chemical Synthesis
3.1.1  Manufacture Of Active Substance Intermediates

3.1.2  Manufacture Of Crude Active Substance

3.1.3  Salt Formation/Purification steps (eg. Crystallisation)
Salt formation, Crystallisation
3.5General Finishing Steps
3.5.1  Physical Processing Steps
Drying, Milling
3.5.2  Primary Packaging

3.5.3  Secondary Packaging

3.6Quality Control Testing
3.6.1  Physical / Chemical testing

BUPRENORPHINE
3.1Manufacture of Active Substance by Chemical Synthesis
3.1.1  Manufacture Of Active Substance Intermediates

3.1.2  Manufacture Of Crude Active Substance

3.1.3  Salt Formation/Purification steps (eg. Crystallisation)
Crystallisation
3.5General Finishing Steps
3.5.1  Physical Processing Steps
Drying, Milling
3.5.2  Primary Packaging

3.5.3  Secondary Packaging

3.6Quality Control Testing
3.6.1  Physical / Chemical testing

OXYCODONE HYDROCHLORIDE
3.1Manufacture of Active Substance by Chemical Synthesis
3.1.1  Manufacture Of Active Substance Intermediates

3.1.2  Manufacture Of Crude Active Substance

3.1.3  Salt Formation/Purification steps (eg. Crystallisation)
Salt formation, Crystallisation
3.5General Finishing Steps
3.5.1  Physical Processing Steps
Drying, Milling
3.5.2  Primary Packaging

3.5.3  Secondary Packaging

3.6Quality Control Testing
3.6.1  Physical / Chemical testing

3.6.2  Microbiological testing (excluding sterility testing)

PHOLCODINE
3.1Manufacture of Active Substance by Chemical Synthesis
3.1.1  Manufacture Of Active Substance Intermediates

3.1.2  Manufacture Of Crude Active Substance

3.1.3  Salt Formation/Purification steps (eg. Crystallisation)
Crystallisation
3.5General Finishing Steps
3.5.1  Physical Processing Steps
Drying, Milling
3.5.2  Primary Packaging

3.5.3  Secondary Packaging

3.6Quality Control Testing
3.6.1  Physical / Chemical testing

Restrictions or Remarks
This certificate is issued based on a desk-based assessment of GMP compliance information provided by the manufacturer. This certificate should be used in combination with the relevant authorisation/registration. A risk-based site inspection programme remains in force.
Contact Details
19/12/2024 Name and signature of the authorised person of the Competent Authority of United Kingdom
Confidential
Medicines and Healthcare products Regulatory Agency
Tel : Confidential